2-Chloro-7-fluoroquinoline-3-carboxaldehyde - CAS 745830-16-4
Catalog: |
BB035114 |
Product Name: |
2-Chloro-7-fluoroquinoline-3-carboxaldehyde |
CAS: |
745830-16-4 |
Synonyms: |
2-chloro-7-fluoroquinoline-3-carbaldehyde |
IUPAC Name: | 2-chloro-7-fluoroquinoline-3-carbaldehyde |
Description: | 2-Chloro-7-fluoroquinoline-3-carboxaldehyde (CAS# 745830-16-4) is a useful research chemical. |
Molecular Weight: | 209.60 |
Molecular Formula: | C10H5ClFNO |
Canonical SMILES: | C1=CC(=CC2=NC(=C(C=C21)C=O)Cl)F |
InChI: | InChI=1S/C10H5ClFNO/c11-10-7(5-14)3-6-1-2-8(12)4-9(6)13-10/h1-5H |
InChI Key: | CZBARWPAXUPUFB-UHFFFAOYSA-N |
Boiling Point: | 339.3 °C at 760 mmHg |
Density: | 1.449 g/cm3 |
LogP: | 2.83980 |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P264, P270, P280, P301+P312, P305+P351+P338, P330, P337+P313, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
AU-2016279661-A1 | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing same as active ingredient | 20150618 |
AU-2016279661-B2 | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing same as active ingredient | 20150618 |
CA-2979815-A1 | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated withpi3 kinases, containing same as active ingredient | 20150618 |
EP-3312175-A1 | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | 20150618 |
JP-2018522852-A | HETEROARYL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING PI3-KINASE RELATED DISEASES COMPRISING THE SAME AS THE ACTIVE INGREDIENT | 20150618 |
Complexity: | 226 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 209.0043696 |
Formal Charge: | 0 |
Heavy Atom Count: | 14 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 0 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 209.0043696 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 30 Å2 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 2.7 |
-
Catalog: BB004566
4-Chloro-5-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine
Detail
-
Catalog: BB005565
5-Fluoro-3,4-diiodo-1H-pyrrolo[2,3-b]pyridine
Detail
-
Catalog: BB007219
2-Fluoro-6-(pyrrolidin-1-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
Detail
-
Catalog: BB001317
2-Fluoro-4-(trifluoromethyl)pyridine-3-carboxylic acid
Detail
-
Catalog: BB002282
Isocytosine
Detail
-
Catalog: BB002685
2-Chloro-4,5-difluorobenzoic acid
Detail
-
Catalog: BB000310
3-Bromo-4-fluorobenzoic acid
Detail
-
Catalog: BB005549
4-Chloro-5-fluoro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine
Detail
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Fluorinated Building Blocks
Other Pyrimidines
Quinoline/Isoquinoline
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS